Chimeric antigen receptor (CAR) T-cells show remarkable therapeutic effects especially in B-cell derived leukemias and lymphomas. However, clinical translation of such an innovative immunotherapeutic approach in highly heterogeneous hematological malignancies like acute myeloid leukemia (AML) or solid tumors is still challenging due to life-threatening side effects, immune escape and disease relapse.

The cell therapy field is experiencing rapid growth with several treatments receiving recent regulatory approval and a number of therapies currently in clinical testing. Manual processing during manufacturing can result in inconsistencies, contamination, and long throughput times.

With the increasing complexity of constructing novel methodologies to further improve clinical outcome of immunotherapies, screening methods to quickly identify the best lead candidates is becoming even more essential.

Join us in Munich whether you are a scientist, clinical researcher, part of a start-up or an established industry company. ICLE 2022 is your opportunity to network and discuss immuno-gene therapy with colleagues from all over the world.